British multinational GlaxoSmithKline has agreed to pay up to €3.7 billion ($4.2 billion) for the rights to Merck KGaA’s next generation cancer immunotherapy.
GSK will pay an initial sum of €300 million for the rights to the experimental drug known as M7824, or bintrafusp alfa. Merck will also be eligible to receive payments of up to €500 million dependent on developmental milestones in lung cancer.
Original Article: GSK buys Merck KGaA's cancer immunotherapy for $4.2 billion